Clinical trials: Seizures, Epileptic
Epilepsy, Generalized Tonic-Clonic Seizures
A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
The purpose of this study is to evaluate the efficacy, safety and tolerability of levetiracetam treatment used as adjunctive therapy in Japanese and Chinese epilepsy patients aged ≥16 years and with uncontrolled Generalized…
- Trial name
- NCT01228747
- Testing
- Levetiracetam
- Where
- 58 sites in China, Japan
- Volunteers
- 361 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled…
- Trial name
- NCT01532726
- Testing
- ESL
- Where
- Portugal
- Volunteers
- 56 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy; Seizure
Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking
The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy. The main questions it aims to answer are: can we develop a future seizure probabilities tool that is more…
- Trial name
- Foresight (NCT06275685)
- Testing
- SeizureWise algorithm, Multi-day Visualizations
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Empatica, Inc.
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00740623
- Testing
- Carisbamate
- Volunteers
- 547 people
- Sponsor
- SK Life Science, Inc.
Generalized Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
- Trial name
- SHINE (NCT06425159)
- Testing
- BHV-7000
- Where
- 109 sites in United States, Australia and 12 more
- Volunteers
- 27 people
- Sponsor
- Biohaven Therapeutics Ltd.
Focal Onset Seizures
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are…
- Trial name
- NCT04836559
- Testing
- JNJ-40411813
- Where
- 69 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
PolG, Primary Mitochondrial Myopathy
Prospective Natural History Study of POLG Disease
The PIONEER study is a prospective, natural history study dedicated to characterizing the clinical progression of POLG-related disorders.
- Trial name
- PIONEER (NCT07775872)
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- The POLG Foundation
Focal Epilepsy
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to…
- Trial name
- ENACT (NCT05481905)
- Testing
- ENX-101
- Where
- 38 sites in United States
- Sponsor
- Engrail Therapeutics INC
Epilepsy, Partial Seizure
RNS System RESPONSE Study
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
- Conditions
- Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy
- Trial name
- RESPONSE (NCT04839601)
- Testing
- RNS System
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- NeuroPace
Epilepsy
Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy
The main objective of the present study will be to establish whether a slow (within 160 days) or a rapid (within 60 days) withdrawal schedule of antiepileptic monotherapy influence relapse rate in adult patients with epilepsy…
- Trial name
- RASLOW (NCT05236166)
- Testing
- Rapid withdrawal of antiepileptic, Slow withdrawal of antiepileptic
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- University Magna Graecia
Focal Onset Seizures
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
- Trial name
- NCT07141329
- Testing
- SPN-817
- Where
- 8 sites in United States, Australia
- Volunteers
- 100 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration)…
- Trial name
- LEADER (NCT00288639)
- Testing
- Pregabalin
- Where
- 8 sites in Greece
- Volunteers
- 98 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Refractory Epilepsy, Focal Seizure
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers…
- Conditions
- Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures
- Trial name
- NCT04770337
- Testing
- STARSTIM device
- Where
- 32 sites in United States, Belgium and 2 more
- Volunteers
- 127 people
- Sponsor
- Neuroelectrics Corporation
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Drug Resistant Epilepsy
Cannabis Extract in Refractory Epilepsy Study
The purpose of this study is to examine whether a low dose of CBD+THC will decrease the frequency of convulsive seizures in adults with drug-resistant epilepsy, when used in addition to standard anti-epileptic drugs (AEDs).
- Trial name
- CERES (NCT03808935)
- Testing
- Medical Cannabis
- Where
- 2 sites in Canada
- Volunteers
- 17 people
- Sponsor
- The Epilepsy Research Program of the Ontario Brain Institute
Epilepsy
Generalized Seizure Detection And Alerting In The EMU With The Empatica Embrace Watch And Smartphone-Based Alert System
To demonstrate safety and effectiveness of the Embrace device in identifying convulsive seizures (CS) and notifying a caregiver during patient hospitalization at an epilepsy monitoring unit (EMU).
- Trial name
- NCT03207685
- Testing
- Additional Seizure Monitoring
- Where
- 2 sites in United States, Italy
- Volunteers
- 100 people
- Sponsor
- Empatica, Inc.
Epilepsy, Partial-onset Seizures
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition…
- Trial name
- NCT01832038
- Testing
- Lacosamide
- Where
- 67 sites in China, Japan
- Volunteers
- 473 people
- Sponsor
- UCB Pharma SA
Childhood Absence Epilepsy, Petit Mal Epilepsy
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.
- Conditions
- Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
- Trial name
- NCT00088452
- Testing
- Ethosuximide, Lamotrigine, Valproic acid
- Where
- 31 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Birth Defects, Pregnancy Complications
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
This is a prospective, observational, exposure-registration and follow-up study of women and their offspring exposed to Keppra® (levetiracetam) and Keppra XR® at the time of conception (i.e., any time from the first day of the…
- Conditions
- Birth Defects, Pregnancy Complications, Epilepsy, Seizures
- Trial name
- NCT00345475
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- UCB Pharma